Drotrecogin alfa (activated)

What is Drotrecogin Alfa (Activated)?

Drotrecogin alfa activated, formerly marketed under the brand name Xigris, was a recombinant form of human activated protein C. This medication was developed and approved for the treatment of adult patients with severe sepsis who had a high risk of death. It represented a significant advancement in the understanding of sepsis pathophysiology at the time of its introduction. However, despite initial promising results, subsequent research led to its withdrawal from the market, making it an important case study in pharmaceutical development and the complexities of treating critical illnesses.

Activated protein C is a naturally occurring serine protease in the human body that plays a crucial role in regulating coagulation and inflammation. Drotrecogin alfa (activated) was designed to mimic the actions of this endogenous protein, aiming to restore balance in the dysregulated systems characteristic of severe sepsis. Its journey from a breakthrough drug to market withdrawal highlights the rigorous and evolving standards for efficacy and safety in critical care medicine.

How Does it Work?

The mechanism of action of Drotrecogin alfa activated is multifaceted, targeting several key pathways involved in the progression of severe sepsis. As a recombinant form of activated protein C, it exerted its therapeutic effects through:

• Anticoagulant Properties: Activated protein C primarily functions as an anticoagulant by inactivating coagulation factors Va and VIIIa. This action helps to inhibit thrombin generation, thereby reducing the formation of microvascular clots that contribute to organ dysfunction in sepsis.
• Anti-inflammatory Effects: Beyond its role in coagulation, activated protein C also possesses significant anti-inflammatory properties. It helps to modulate the inflammatory response by inhibiting the production of pro-inflammatory cytokines and reducing leukocyte adhesion to endothelial cells. This can mitigate the widespread inflammatory damage observed in sepsis.
• Profibrinolytic Activity: It enhances fibrinolysis by inactivating plasminogen activator inhibitor-1 (PAI-1), which normally inhibits the breakdown of clots. By promoting clot lysis, it helps to clear existing microthrombi and improve microcirculatory perfusion.
• Endothelial Protection: Activated protein C has been shown to protect endothelial cells from injury and dysfunction, which are critical components of septic shock pathology. It helps maintain endothelial barrier integrity and reduces apoptosis.

By simultaneously addressing the coagulation abnormalities, excessive inflammation, and endothelial damage, Drotrecogin alfa activated aimed to interrupt the vicious cycle that characterizes severe sepsis, thereby improving patient outcomes.

Medical Uses

Historically, the sole approved medical use for Drotrecogin alfa activated was for the treatment of adult patients with severe sepsis who had a high risk of death. Severe sepsis is a life-threatening condition caused by the body's overwhelming response to infection, leading to widespread inflammation, organ dysfunction, and often septic shock.

When it was first introduced, Drotrecogin alfa (activated) was considered a significant therapeutic option for this critical condition, based on the results of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study, which showed a reduction in mortality in patients with severe sepsis. However, subsequent trials, particularly the PROWESS-SHOCK study, failed to demonstrate a significant survival benefit in a broader population of patients with septic shock. This lack of confirmed efficacy, coupled with the significant bleeding risk associated with the drug, led to its voluntary withdrawal from the global market by its manufacturer in 2011.

Therefore, it is crucial to understand that while Drotrecogin alfa activated once held promise, it is no longer used in clinical practice for severe sepsis or any other condition.

Dosage

When Drotrecogin alfa activated was in clinical use, the standard dosage for adult patients with severe sepsis was a continuous intravenous infusion of 24 micrograms per kilogram of body weight per hour (24 mcg/kg/hr) for a total duration of 96 hours. The administration required a dedicated intravenous line and careful monitoring due to the potential for serious adverse effects.

Dosage adjustments were not typically recommended for renal or hepatic impairment, but the drug was contraindicated in patients with active bleeding or those at high risk of bleeding, such as those with severe coagulopathy, recent surgery, trauma, or intracranial pathology. The precise weight-based dosing and continuous infusion protocol were critical to maintaining therapeutic levels while attempting to manage the associated risks. Due to its withdrawal, these dosage guidelines are now primarily of historical and academic interest.

Side Effects

The most significant and concerning side effect associated with Drotrecogin alfa activated was an increased bleeding risk. This was directly related to its potent anticoagulant properties. Serious bleeding events included:

• Intracranial Hemorrhage: Bleeding within the brain, which could be life-threatening or lead to severe neurological impairment.
• Gastrointestinal Bleeding: Hemorrhage in the digestive tract, ranging from subtle blood loss to massive, life-threatening events.
• Other Hemorrhages: Bleeding from surgical sites, urinary tract, retroperitoneal space, and other areas.

The risk of bleeding was carefully weighed against the potential benefits, especially in critically ill patients who often have multiple comorbidities and are already at an elevated risk for bleeding. Other less common side effects could include skin rash, bruising, and allergic reactions. The severity and prevalence of bleeding complications ultimately played a major role in the re-evaluation of the drug's risk-benefit profile and its subsequent withdrawal from the market.

Drug Interactions

Due to its potent anticoagulant activity, Drotrecogin alfa activated had several significant drug interactions, primarily with other medications that affect blood coagulation or platelet function. Concomitant use with these agents substantially increased the bleeding risk for patients.

• Anticoagulants: The co-administration of Drotrecogin alfa (activated) with other anticoagulants such as unfractionated heparin, low molecular weight heparins, warfarin, or direct oral anticoagulants was generally contraindicated or required extreme caution and intensive monitoring. The additive anticoagulant effect could lead to severe or fatal hemorrhage.
• Antiplatelet Agents: Medications that inhibit platelet aggregation, such as aspirin, clopidogrel, prasugrel, ticagrelor, or NSAIDs, also increased the risk of bleeding when used concurrently with Drotrecogin alfa (activated).
• Thrombolytic Agents: Drugs used to dissolve existing clots, such as alteplase or reteplase, would dramatically increase the risk of bleeding if given with Drotrecogin alfa (activated).
• Other Medications: Any drug known to affect coagulation or increase the risk of bleeding, even indirectly, would necessitate careful consideration and monitoring if a patient were to receive Drotrecogin alfa (activated).

Given its withdrawal from the market, these drug interaction concerns are now part of its historical safety profile, serving as a reminder of the complexities of managing coagulation in critically ill patients.

FAQ

Q: Is Drotrecogin Alfa (Activated) still used in medicine today?

A: No, Drotrecogin alfa activated was voluntarily withdrawn from the global market in 2011 due to a lack of confirmed efficacy in a subsequent clinical trial (PROWESS-SHOCK) and concerns over its associated bleeding risk.

Q: What was Drotrecogin Alfa (Activated) primarily used for?

A: It was approved and used for the treatment of adult patients with severe sepsis who had a high risk of death.

Q: What was the brand name for Drotrecogin Alfa (Activated)?

A: The brand name for Drotrecogin alfa activated was Xigris.

Q: What were the main risks associated with Drotrecogin Alfa (Activated)?

A: The most significant risk was serious bleeding, including intracranial hemorrhage and gastrointestinal bleeding, due to its potent anticoagulant properties.

Q: What is activated protein C?

A: Activated protein C is a natural protein in the human body that plays a key role in regulating blood clotting and inflammation. Drotrecogin alfa activated was a recombinant form designed to mimic its actions.

Products containing Drotrecogin alfa (activated) are available through trusted online pharmacies. You can browse Drotrecogin alfa (activated)-based medications at ShipperVIP or Medicenter.

Summary

Drotrecogin alfa activated, known by its brand name Xigris, represents a complex chapter in the history of critical care medicine. Initially hailed as a breakthrough for severe sepsis, a life-threatening condition, this recombinant human activated protein C aimed to combat the disease by leveraging its anticoagulant, anti-inflammatory, and profibrinolytic properties. Its mechanism involved inactivating key coagulation factors, modulating inflammatory responses, and enhancing clot breakdown, thereby addressing the multi-organ dysfunction characteristic of sepsis.

Despite initial positive results that led to its approval, subsequent rigorous clinical trials failed to consistently demonstrate a significant survival benefit across diverse patient populations. This, combined with a notable bleeding risk – particularly serious intracranial and gastrointestinal hemorrhages – ultimately led to its voluntary withdrawal from the market in 2011. The story of Drotrecogin alfa activated underscores the challenges in treating complex syndromes like sepsis and highlights the continuous evolution of evidence-based medicine, where even initially promising therapies must withstand the test of extensive clinical scrutiny to ensure both efficacy and safety for patients.